The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

By L. Bao, Wei Deng, Baoying Huang, Hong Gao, Jiangning Liu, L. Ren, Q. Wei, Pin Yu, Yanfeng Xu, Feifei Qi and 39 more. Nature, 2020

1,132 citations recorded by the source corpus.

Subfields: Infectious Diseases, Neurology

View Paper: https://www.semanticscholar.org/paper/27eb1d3a2bae22ece294182f53bb092694eb62c3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

In Neurology

Citations in the corpus

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment (2020, positive): “Utilizing the herein established transcriptional and functional phenotypes of the myeloid cell compartment, it will likely be possible to estimate the potential contribution of the causes mentioned above in larger clinical studies in the future and to address potential upstream events of immune dysr”
SARS-CoV-2 Vaccines: Status Report (2020, background): “Initial work showed that it can use angiotensin-converting enzyme 2 (ACE2) from bats, civet cats, swine, cats, ferrets, non-human primates (NHPs), and humans as a receptor (Letko et al., 2020;Wan et al., 2020; Zhou et al., 2020).”
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells (2020, positive): “Additionally, in vivo experiments conﬁrmed that BD-368-2 could provide strong therapeutic efﬁcacy and prophylactic protection against SARS-CoV-2, using the hACE2 transgenic mice model (Bao et al., 2020; Yang et al., 2007; McCray et al., 2007).”
Mechanisms of SARS-CoV-2 Transmission and Pathogenesis (2020, positive): “One of these strategies is to genetically modify mice to express human ACE2 (hACE2) (humanized mice) under the epithelial cell-specific cytokeratin-18 (Krt(18)) promoter [114], a universal chicken beta-actin promoter [115], or the endogenousmACE2 promoter [113].”
A Mouse Model of SARS-CoV-2 Infection and Pathogenesis (2020, positive): “The peaked viral RNA loads in lung reached 108 copies/g, which is much higher than that in hACE2 transgenic mice (Bao et al., 2020).”
COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection (2021, background): “Noteworthy, SARS-CoV-2 enters into host cells after binding to ACE2 receptor [99], and both SARS-CoV-2 and ACE2 are internalized by endocytosis, so that surface ACE2 is then downregulated, resulting in unopposed Ang II accumulation [9].”
Virology, Epidemiology, Pathogenesis, and Control of COVID-19 (2020, background): “Human ACE2 transgenic mouse and rhesus monkey models of COVID-19 have been well established for vaccine development [84], and someSARS-CoV-2 vaccines are already under clinical trial [85,86].”
Animal models for COVID-19 (2020, background): “…mouse models, in which human ACE2 is under the expression of a tissue-specific promoter (for example, the Krt18 promoter for epithelial cells 10 ; K18-hACE2 mice), a universal promoter (cytomegalovirus enhancer followed by the chicken β-actin promoter 11 ) or the endogenous mouse Ace2 promoter 12 .”